Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM359 in Chronic Granulomatous Disease
NCT06559176Phase 2Enrolling by invitation
- Sponsor
- Prime Medicine, Inc.
- Start
- Oct 2024
- Primary completion
- Jan 2030
- Modality
- Gene Silencing, Prime Editing, Cell Therapies
- Countries
- 3
01
Overview
A Phase 2 trial of PM359 in chronic granulomatous disease (CGD), sponsored by Prime Medicine, Inc.. Started Oct 2024; status: enrolling by invitation.
02
Drugs
PM359
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT06559176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06559176.